$DNA is once again on NYSE; FDA clears Soliris chal­lenger for the mar­ket; Flag­ship’s think­ing big again with eR­NA; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

I still re­mem­ber the un­cer­tain­ty in the air last year when no­body was sure whether AS­CO would can­cel their in-per­son meet­ing. But it’s now back again for the sec­ond vir­tu­al con­fer­ence, and End­points News is here for it. Check out our 2-day event re­view­ing the land­scape of can­cer R&D and send news our way.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.